Abstract:The study explored novel Haspin kinase inhibitors using the Chembridge library. We identified ligands based on chemical features, docking scores, and binding strength. Compound 16503395 inhibits Haspin kinase function at 72 % at 10 μM, with an IC50 value of 2.6 μM and is claimed to be a selective and potential Haspin kinase inhibitor. Structure‐based virtual screening is efficient method for finding novel scaffolds/molecules for biological targets. Due to the accessibility of the Haspin crystal structure and its prevalence in various diseases; we sought exploring novel Haspin kinase inhibitors. We used the commercially available Chembridge library for virtual screening which had nearly 7,00,000 compounds. We employed variety of computational tools such as molecular docking, molecular dynamics simulations, in silico pharmacokinetics analysis to identify novel inhibitors targeting Haspin kinase. Based on chemical features, docking score, and MMGB/SA binding strength, 10 ligands were chosen. On in vitro determination, one chemical entity was found to inhibit Haspin's enzyme function at 72 % at 10 μM. Compound 16503395 had higher selectivity over Haspin kinase activity than the other kinases. The IC50 value for the compound 16503395 that inhibits Haspin kinase significantly was determined and was found to be 2.6 μM. After subjecting to molecular dynamics simulation analysis for compound 16503395 Haspin protein complex, we found that the Haspin kinase binding site amino acid unique residues Gly608, Glu492, Lys511, Asn654, Asp687, Ala503, Leu656 and Phe605 play important role in binding kinetics. We claim 5‐(hydroxymethyl)‐N‐[cis‐3‐(6‐oxo‐2‐pyrrolidin‐1‐yl‐1,6‐dihydropyrimidin‐4‐yl)cyclobutyl]‐2‐furamide (16503395) as a selective and potential Haspin kinase inhibitor.

Thieno[3,2‐b]pyridine: Attractive scaffold for highly selective inhibitors of underexplored protein kinases with variable binding mode

High-Throughput Kinase Profiling: A More Efficient Approach toward the Discovery of New Kinase Inhibitors

Structure-Based Discovery of Small Molecule Inhibitors Targeted to Protein Tyrosine Phosphatase 1B

Identification of Novel Thiazolo[5,4-<i>b</i>]Pyridine Derivatives as Potent Phosphoinositide 3-Kinase Inhibitors

Discovery of an Allosteric, Inactive Conformation-Selective Inhibitor of Full-Length HPK1 Utilizing a Kinase Cascade Assay

Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors

N1‐Benzoylated 5‐(4‐pyridinyl)indazole‐based kinase inhibitors: Attaining haspin and Clk4 selectivity via modulation of the benzoyl substituents

Discovery of Non-ATP-Competitive Inhibitors of Polo-like Kinase 1.

Design, Synthesis and Activity of Mnk1 and Mnk2 Selective Inhibitors Containing Thieno[2,3-D]pyrimidine Scaffold.

Discovery of a New Dihydropyrimidinone Derivative as a Potential Haspin Kinase Inhibitor: Structure‐Guided Insights, In‐Vitro and Molecular Dynamics‐Based Validation

Discovery and Sar of A Novel Selective and Orally Bioavailable Nonpeptide Classical Competitive Inhibitor Class of Protein-Tyrosine Phosphatase 1B

Pyridyl-Pyrimidine Benzimidazole Derivatives As Potent, Selective, and Orally Bioavailable Inhibitors of Tie-2 Kinase

Dynamic and Multi-Pharmacophore Modeling for Designing Polo-Box Domain Inhibitors

Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships

Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors.

Identification of Pyrimidine-Based Lead Compounds for Understudied Kinases Implicated in Driving Neurodegeneration

Discovery of Thieno[3,2-C]pyridin-4-amines As Novel Bruton's Tyrosine Kinase (BTK) Inhibitors.

Synthesis and biological evaluation of novel 7-substituted 3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.

Identification and Optimisation of Novel and Selective Small Molecular Weight Kinase Inhibitors of Mtor

Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors

Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.